Express Scripts to cover psoriasis cream from MC2 Therapeutics

Just three months after MC2 Therapeutics and Epi Health officially commenced the launch of Wynzora, a plaque psoriasis cream, on the US market, the country's biggest pharmacy benefit management company, Express Scripts, has announced it will cover the drug on its National Preferred Formulary.

Photo: MC2 Therapeutics / PR

The biotech company MC2 Therapeutics has had its plaque psoriasis cream Wynzora added to the drug program of the biggest pharmacy benefit manager (PMD) in the US, Express Scripts, the Danish biotech company reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs